Dublin, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The "Global Sickle Cell Anemia Testing & Screening Market by Technology, Age Group, Sector - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.
The Global Sickle Cell Anemia Testing & Screening Market size was estimated at USD 832.68 million in 2022, USD 943.95 million in 2023, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 13.49% to reach USD 2,293.22 million by 2030.
In this report, 2018 to 2021 are considered as historical years, 2022 is the base year, 2023 is the estimated year, and years from 2024 to 2030 are considered as forecast periods.
The report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.
The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share.
The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.
The report answers questions such as:
- What is the market size and forecast of the Global Sickle Cell Anemia Testing & Screening Market?
- What are the inhibiting factors and impact of COVID-19 shaping the Global Sickle Cell Anemia Testing & Screening Market during the forecast period?
- Which are the products/segments/applications/areas to invest in over the forecast period in the Global Sickle Cell Anemia Testing & Screening Market?
- What is the competitive strategic window for opportunities in the Global Sickle Cell Anemia Testing & Screening Market?
- What are the technology trends and regulatory frameworks in the Global Sickle Cell Anemia Testing & Screening Market?
- What is the market share of the leading vendors in the Global Sickle Cell Anemia Testing & Screening Market?
- What modes and strategic moves are considered suitable for entering the Global Sickle Cell Anemia Testing & Screening Market?
Market Dynamics
Drivers
- Prevalence of Sickle Cell Disease Worldwide
- Ongoing Government Initiatives to Support the Diagnosis
- Significant Use of High-Performance Liquid Chromatography (HPLC) Testing for Sickle Cell
Restraints
- Diagnostic & Treatment Issues Associated with Sickle Cell Anemia
Opportunities
- Developing a Deep Learning Framework Designed to Perform Automated Screening of Sickle Cell Anemia
- Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
Challenges
- Clinical Heterogeneity and Complications Associated with SCD
- Lack of Resources and Skilled Clinical Laboratory Workforce Shortages
Market Segmentation & Coverage:
The Global Sickle Cell Anemia Testing & Screening Market research report categorizes the market and provides revenue forecasts and trend analysis for the following sub-markets:
- Technology: Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC), and Point-of-Care Tests, with Point-of-Care Tests commanding the largest market share of 37.96% in 2022, followed by Hemoglobin Electrophoresis.
- Age Group: Adult Screening, Newborn Screening, and Years 1 to 25, with Newborn Screening commanding the largest market share of 61.89% in 2022, followed by Years 1 to 25.
- Sector: Corporate Labs, Government Labs, Private Labs, and Public-Private-Partnerships, with Corporate Labs commanding the largest market share of 42.17% in 2022, followed by Private Labs.
- Region: The Americas commanded the largest market share of 36.84% in 2022, followed by Europe, Middle East & Africa.
Competitive Portfolio:
- Agios Pharmaceuticals, Inc.
- Anamol Laboratories Pvt. Ltd.
- Atlas Medical GmbH
- Bio Lab Diagnostics (I) Private Limited
- Bio-Rad Laboratories, Inc.
- Biomedomics Inc.
- Bluebird bio, Inc.
- Calibre Scientific, Inc.
- CRISPR Therapeutics
- Edvotek Inc.
- Global Blood Therapeutics, Inc.
- Hemex Health
- HiMedia Laboratories
- Laboratory Corporation of America Holdings
- Maternova Inc.
- PerkinElmer, Inc.
- PicnicHealth
- Quest Diagnostics Incorporated
- Silver Lake Research Corporation
- Streck, Inc.
- Thermo Fisher Scientific Inc.
- Ulta Lab Tests, LLC
- Vertex Pharmaceuticals Incorporated
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 193 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $943.95 Million |
| Forecasted Market Value (USD) by 2030 | $2293.22 Million |
| Compound Annual Growth Rate | 13.4% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/l1vwnb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
